ABBV241227C167500
- 6.00
- 0.000.00%
AbbVie Newsroom
AbbVie (ABBV) Benefitted From Top-Line Growth From Its Immunosuppressive Drugs
Is AbbVie Stock a Buy?
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution
AbbVie Hits 4-week Low
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of...
Express News | Abbvie's Atogepant and Onabotulinumtoxina Receive Strong Recommendations in the Newly Updated Canadian Headache Society (Chs) Migraine Prevention Guideline
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now?
AbbVie's Tavapadon Achieves Positive Topline Results in Phase III TEMPO-2 Trial
Investors Heavily Search AbbVie Inc. (ABBV): Here Is What You Need to Know
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Piper Sandler has raised AbbVie's Target Price to $220.
Gelonghui, December 18: Piper Sandler has raised AbbVie's Target Price from $212 to $220, maintaining a "Shareholding" rating. (Gelonghui)
AbbVie Analyst Ratings
4 Big Drug Stocks That May Continue to Outperform in 2025
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Express News | Abbvie : Piper Sandler Raises Target Price to $220 From $212
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors